跳转至内容
Merck
所有图片(1)

Key Documents

View All Documentation

A4978

Sigma-Aldrich

阿屈膦酸盐 钠 三水合物

≥97% (NMR), powder

别名:

4-氨基-1-羟基-1-膦酸丁酯，单钠, MK-217

登录查看公司和协议定价
所有图片(1)

About This Item

经验公式（希尔记法）:
C4H12NaNO7P2 · 3 H2O
CAS号:
121268-17-5
分子量:
325.12
MDL號碼:
MFCD01748233
分類程式碼代碼:
41106300
PubChem物質ID:
24724391
NACRES:
NA.77

品質等級

100

化驗

≥97% (NMR)

形狀

powder

顏色

white

溶解度

water, double-distilled: 10 mg/mL

儲存溫度

−20°C

SMILES 字串

[Na+].[H]O[H].[H]O[H].[H]O[H].NCCCC(O)(P(O)(O)=O)P(O)([O-])=O

InChI

1S/C4H13NO7P2.Na.3H2O/c5-3-1-2-4(6,13(7,8)9)14(10,11)12;;;;/h6H,1-3,5H2,(H2,7,8,9)(H2,10,11,12);;3*1H2/q;+1;;;/p-1

InChI 密鑰

DCSBSVSZJRSITC-UHFFFAOYSA-M

基因資訊

human ... FDPS(2224)

正在寻找类似产品? 访问 产品对比指南

應用

阿仑膦酸钠三水合物已被用于：
  • 钛植入物的磷酸钙纳米颗粒（nCaP）二膦酸盐（BP）涂层并用于分析其成骨能力
  • 从老年骨质疏松症患者和健康人群中分离的人骨髓基质细胞（hBMSC）的成骨分化
  • 处理成骨细胞祖细胞和成骨细胞并通过传统测定和简单的数字图象分析研究其对成骨细胞行为的影响

    • 生化／生理作用

    阿伦膦酸盐是一种含氮二膦酸盐，可阻断甲羟戊酸途径 并限制破骨功能和活性。阿仑膦酸钠三水合物是一种骨吸收抑制剂、法尼基二磷酸合成酶抑制剂和 CD45 蛋白酪氨酸磷酸酶抑制剂。
    阿仑膦酸钠三水合物是一种骨吸收抑制剂；法尼基二磷酸合成酶抑制剂 (IC 50 = 460 nM)；CD45 蛋白酪氨酸磷酸酶抑制剂。

    儲存和穩定性

    重溶后，建议在-20°C下分装冻存。储备液在-20°C条件下可稳定保存6个月。

    象形圖

    Exclamation mark
    GHS07

    訊號詞

    Warning

    危險聲明

    H302

    危險分類

    Acute Tox. 4 Oral

    儲存類別代碼

    11 - Combustible Solids

    水污染物質分類（WGK）

    WGK 3

    閃點（°F）

    Not applicable

    閃點（°C）

    Not applicable

    個人防護裝備

    dust mask type N95 (US), Eyeshields, Gloves

    分析证书(COA)

    输入产品批号来搜索 分析证书(COA) 。批号可以在产品标签上"批“ （Lot或Batch）字后找到。

    已有该产品？

    在文件库中查找您最近购买产品的文档。

    访问文档库

    Robert Josse et al.
    Current medical research and opinion, 29(3), 205-216 (2013-01-10)
    According to the 2010 Osteoporosis Canada Clinical Practice Guidelines, denosumab is a first-line option for the pharmacological management of postmenopausal osteoporosis (PMO), along with several therapeutics that may be more familiar to family practice doctors: bisphosphonates, raloxifene, teriparatide, and hormone
    Mattias Ulmner et al.
    Journal of oral and maxillofacial surgery : official journal of the American Association of Oral and Maxillofacial Surgeons, 72(1), 76-82 (2013-09-03)
    To estimate the incidence of bisphosphonate (BP)-related osteonecrosis of the jaw (BRONJ) associated with the use of oral BPs and osteonecrosis of the jaw (ONJ) not associated with current or previous medication with a BP or radiotherapy to the head
    Shmuel Banai et al.
    American heart journal, 165(2), 234-240 (2013-01-29)
    Activation of systemic innate immunity is critical in the chain of events leading to restenosis. LABR-312 is a novel compound that transiently modulates circulating monocytes, reducing accumulation of these cells at vascular injury sites and around stent struts. The purpose
    Xuefeng Hu et al.
    Tissue engineering. Part A, 19(17-18), 1919-1930 (2013-04-02)
    Fibrous encapsulation can impair implant osseointegration and cause implant failure but currently there are limited strategies to address this problem. Since bisphosphonates (BPs), a class of drugs widely used to treat bone diseases, was recently found to induce fibroblast apoptosis
    Wei-Yih Chiu et al.
    The Journal of clinical endocrinology and metabolism, 98(4), E723-E726 (2013-03-09)
    Bisphosphonates effectively increase bone mineral density and reduce fracture risk in patients with osteoporosis, but there are concerns about osteonecrosis of the jaw (ONJ) and atypical femoral fractures (AFFs) in the long-term users. So far both complications have not been
    查看所有相关文献

    我们的科学家团队拥有各种研究领域经验，包括生命科学、材料科学、化学合成、色谱、分析及许多其他领域.

    联系技术服务部门